
## Michael Pawlita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4655624/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute, 2016, 108, djv403.	3.0	580
2	Multiplex Human Papillomavirus Serology Based on In Situ–Purified Glutathione S-Transferase Fusion Proteins. Clinical Chemistry, 2005, 51, 1845-1853.	1.5	486
3	Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. Journal of Clinical Oncology, 2013, 31, 2708-2715.	0.8	280
4	Suppression of non-specific binding in serological Luminex assays. Journal of Immunological Methods, 2006, 309, 200-204.	0.6	251
5	Human Papillomavirus Infection and Incidence of Squamous Cell and Basal Cell Carcinomas of the Skin. Journal of the National Cancer Institute, 2006, 98, 389-395.	3.0	229
6	A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. Journal of Immunological Methods, 2001, 253, 153-162.	0.6	208
7	Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncology, The, 2016, 17, 67-77.	5.1	183
8	Viral RNA Patterns and High Viral Load Reliably Define Oropharynx Carcinomas with Active HPV16 Involvement. Cancer Research, 2012, 72, 4993-5003.	0.4	152
9	Seroprevalence of 34 Human Papillomavirus Types in the German General Population. PLoS Pathogens, 2008, 4, e1000091.	2.1	145
10	Multicenter Study of the Association between Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma. Cancer Research, 2010, 70, 9777-9786.	0.4	130
11	HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. Journal of Virological Methods, 2002, 106, 61-70.	1.0	122
12	Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine, 2018, 36, 4783-4791.	1.7	117
13	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. American Journal of Epidemiology, 2013, 178, 877-884.	1.6	116
14	Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study. Journal of the National Cancer Institute, 2013, 105, 536-545.	3.0	115
15	<i>Helicobacter pylori</i> Multiplex Serology. Helicobacter, 2009, 14, 525-535.	1.6	112
16	Seroepidemiology of Human Polyomaviruses in a US Population. American Journal of Epidemiology, 2016, 183, 61-69.	1.6	111
17	Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1874-1879.	1.1	106
18	Highâ€risk HPV types and head and neck cancer. International Journal of Cancer, 2014, 135, 1653-1661.	2.3	97

#	Article	IF	CITATIONS
19	Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16â€driven oropharyngeal squamous cell carcinoma. International Journal of Cancer, 2017, 140, 2748-2757.	2.3	92
20	Human Papillomavirus Load in Eyebrow Hair Follicles and Risk of Cutaneous Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 719-727.	1.1	84
21	Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. Gastroenterology, 2019, 156, 175-186.e2.	0.6	84
22	Genus  human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ: British Medical Journal, 2010, 341, c2986-c2986.	2.4	82
23	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	77
24	Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 189-195.	1.1	76
25	Race, African Ancestry, and Helicobacter pylori Infection in a Low-Income United States Population. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 826-834.	1.1	76
26	<i>Helicobacter pylori</i> Infection and Gastric Cancer Risk: Evaluation of 15 <i>H. pylori</i> Proteins Determined by Novel Multiplex Serology. Cancer Research, 2009, 69, 6164-6170.	0.4	72
27	Case–Control Study of Cutaneous Human Papillomaviruses in Squamous Cell Carcinoma of the Skin. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1303-1313.	1.1	64
28	Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study. American Journal of Transplantation, 2018, 18, 1220-1230.	2.6	62
29	Association between Chronic Atrophic Gastritis and Serum Antibodies to 15 Helicobacter pylori Proteins Measured by Multiplex Serology. Cancer Research, 2009, 69, 2973-2980.	0.4	61
30	Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: A populationâ€based study. International Journal of Cancer, 2013, 133, 1713-1720.	2.3	60
31	Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPVâ€associated cancers. International Journal of Cancer, 2008, 123, 2626-2631.	2.3	59
32	Prospective Study of <i>Helicobacter pylori</i> Biomarkers for Gastric Cancer Risk among Chinese Men. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2185-2192.	1.1	56
33	Case–control study of genusâ€beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. International Journal of Cancer, 2014, 134, 2231-2244.	2.3	56
34	Association of seropositivity to <i>Helicobacter</i> species and biliary tract cancer in the ATBC study. Hepatology, 2014, 60, 1963-1971.	3.6	56
35	Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. International Journal of Cancer, 2007, 120, 2459-2465.	2.3	54
36	Case–control Study of Merkel Cell Polyomavirus Infection and Cutaneous Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 74-81.	1.1	54

#	Article	IF	CITATIONS
37	Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study. Journal of Clinical Oncology, 2015, 33, 877-884.	0.8	53
38	<i>Helicobacter pylori</i> blood biomarker for gastric cancer risk in East Asia. International Journal of Epidemiology, 2016, 45, 774-781.	0.9	53
39	Antibodies against highâ€risk human papillomavirus proteins as markers for invasive cervical cancer. International Journal of Cancer, 2014, 135, 2453-2461.	2.3	51
40	Prospective Study of Human Papillomavirus Seropositivity and Risk of Nonmelanoma Skin Cancer. American Journal of Epidemiology, 2012, 175, 685-695.	1.6	50
41	Role of human papillomavirus infection in the etiology of vulvar cancer in Italian women. Infectious Agents and Cancer, 2020, 15, 20.	1.2	50
42	A CagAâ€independent cluster of antigens related to the risk of noncardia gastric cancer: Associations between <i>Helicobacter pylori</i> antibodies and gastric adenocarcinoma explored by multiplex serology. International Journal of Cancer, 2014, 134, 2942-2950.	2.3	49
43	Case–Control Study of Cutaneous Human Papillomavirus Infection in Basal Cell Carcinoma of the Skin. Journal of Investigative Dermatology, 2013, 133, 1512-1520.	0.3	48
44	High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses. PLoS ONE, 2013, 8, e75677.	1.1	48
45	Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. Journal of General Virology, 2009, 90, 1986-1998.	1.3	47
46	Fruit and vegetable consumption, <i>Helicobacter pylori</i> antibodies, and gastric cancer risk: A pooled analysis of prospective studies in China, Japan, and Korea. International Journal of Cancer, 2017, 140, 591-599.	2.3	47
47	Association of <scp><i>S</i></scp> <i>treptococcus gallolyticus</i> subspecies <i>gallolyticus</i> with colorectal cancer: Serological evidence. International Journal of Cancer, 2016, 138, 1670-1679.	2.3	46
48	Helicobacter pylori Protein–Specific Antibodies and Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1964-1974.	1.1	45
49	Autophagy regulates UBC9 levels during viral-mediated tumorigenesis. PLoS Pathogens, 2017, 13, e1006262.	2.1	44
50	Helicobacter pylori antibody patterns in Germany: a cross-sectional population study. Gut Pathogens, 2014, 6, 10.	1.6	42
51	Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget, 2016, 7, 16420-16432.	0.8	42
52	Multiplex <i>H. pylori</i> Serology and Risk of Gastric Cardia and Noncardia Adenocarcinomas. Cancer Research, 2015, 75, 4876-4883.	0.4	39
53	Validation of Multiplex Serology detecting human herpesviruses 1-5. PLoS ONE, 2018, 13, e0209379.	1.1	39
54	Prevalence and stability of antibodies to 37 human papillomavirus types — A population-based longitudinal study. Virology, 2010, 407, 26-32.	1.1	37

#	Article	IF	CITATIONS
55	The Presence of Betapapillomavirus Antibodies around Transplantation Predicts the Development of Keratinocyte Carcinoma in Organ Transplant Recipients: A Cohort Study. Journal of Investigative Dermatology, 2015, 135, 1275-1282.	0.3	37
56	Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. International Journal of Cancer, 2015, 136, 138-151.	2.3	34
57	Smoking, <i>Helicobacter Pylori</i> Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea. Cancer Prevention Research, 2019, 12, 667-674.	0.7	33
58	Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiology, 2016, 42, 46-52.	0.8	32
59	Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Lancet Infectious Diseases, The, 2021, 21, 1458-1468.	4.6	28
60	Risk Factors for Cutaneous Human Papillomavirus Seroreactivity among Patients Undergoing Skin Cancer Screening in Florida. Journal of Infectious Diseases, 2010, 201, 760-769.	1.9	26
61	Prospective evaluation of antibody response to <i>Streptococcus gallolyticus</i> and risk of colorectal cancer. International Journal of Cancer, 2018, 143, 245-252.	2.3	25
62	Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. Npj Vaccines, 2020, 5, 14.	2.9	25
63	The Association between Cutaneous Squamous Cell Carcinoma and Betapapillomavirus Seropositivity: a Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1171-1177.	1.1	24
64	Sunlight Exposure and Cutaneous Human Papillomavirus Seroreactivity in Basal Cell and Squamous Cell Carcinomas of the Skin. Journal of Infectious Diseases, 2012, 206, 399-406.	1.9	23
65	Serology of <i>Streptococcus gallolyticus</i> subspecies <i>gallolyticus</i> and its association with colorectal cancer and precursors. International Journal of Cancer, 2017, 141, 897-904.	2.3	23
66	Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 75-81.	4.5	23
67	Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infectious Diseases, 2014, 14, 120.	1.3	22
68	Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 163-171.	4.5	21
69	Antibody Responses to Streptococcus Gallolyticus Subspecies Gallolyticus Proteins in a Large Prospective Colorectal Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1186-1194.	1.1	21
70	Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank. EBioMedicine, 2020, 62, 103123.	2.7	21
71	Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain. Frontiers in Microbiology, 2017, 8, 888.	1.5	20
72	Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 219-223.	1.1	19

#	Article	IF	CITATIONS
73	Racial Differences in <i>Helicobacter pylori</i> CagA Sero-prevalence in a Consortium of Adult Cohorts in the United States. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2084-2092.	1.1	18
74	Antibody Responses to <i>Fusobacterium nucleatum</i> Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1552-1555.	1.1	17
75	Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer. Clinical Epigenetics, 2022, 14, 1.	1.8	17
76	Prospective study of <scp><i>H</i></scp> <i>elicobacter pylori</i> antigens and gastric noncardia cancer risk in the nutrition intervention trial cohort. International Journal of Cancer, 2015, 137, 1938-1946.	2.3	16
77	<scp>Epsteinâ€Barr</scp> virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country. International Journal of Cancer, 2020, 147, 461-471.	2.3	16
78	Validation of a Blood Biomarker for Identification of Individuals at High Risk for Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1472-1479.	1.1	15
79	Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Research, 2021, 81, 4628-4638.	0.4	15
80	The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK. Infectious Agents and Cancer, 2009, 4, 13.	1.2	14
81	Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma. Infectious Agents and Cancer, 2015, 10, 35.	1.2	14
82	Helicobacter pylori serological biomarkers of gastric cancer risk in the MCC-Spain case-control Study. Cancer Epidemiology, 2017, 50, 76-84.	0.8	14
83	Disease trajectories, place and mode of death in people with head and neck cancer: Findings from the â€~Head and Neck 5000' population-based prospective clinical cohort study. Palliative Medicine, 2020, 34, 639-650.	1.3	14
84	Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. Journal of Clinical Oncology, 2022, 40, 3613-3622.	0.8	14
85	Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. Clinical Cancer Research, 2019, 25, 7405-7412.	3.2	13
86	Differences in antibody levels to H. pylori virulence factors VacA and CagA among African Americans and whites in the Southeast USA. Cancer Causes and Control, 2020, 31, 601-606.	0.8	13
87	HPV DNA genotyping, HPV E6*I mRNA detection, and p16INK4a/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study. Cancer Epidemiology, 2021, 72, 101925.	0.8	13
88	Performance of multiplex serology in discriminating active vs past <i>Helicobacter pylori</i> infection in a primarily African American population in the southeastern United States. Helicobacter, 2020, 25, e12671.	1.6	12
89	<i>Helicobacter pylori</i> Blood Biomarkers and Gastric Cancer Survival in China. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 342-344.	1.1	11
90	Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia. Digestive Diseases and Sciences, 2018, 63, 2765-2772.	1.1	11

#	Article	IF	CITATIONS
91	Antibody Responses to <i>Helicobacter pylori</i> and Risk of Developing Colorectal Cancer in a European Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1475-1481.	1.1	11
92	HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer. Oral Oncology, 2020, 107, 104721.	0.8	10
93	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nature Communications, 2021, 12, 5945.	5.8	10
94	Lack of association between the presence and persistence of betapapillomavirus DNA in eyebrow hairs and betapapillomavirus L1 antibodies in serum. Journal of General Virology, 2010, 91, 2073-2079.	1.3	9
95	Human polyomaviruses and incidence of cutaneous squamous cell carcinoma in the New Hampshire skin cancer study. Cancer Medicine, 2016, 5, 1239-1250.	1.3	8
96	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. International Journal of Cancer, 2019, 145, 3436-3444.	2.3	8
97	Epstein Barr virus antibody reactivity and gastric cancer: A population-based case-control study. Cancer Epidemiology, 2019, 61, 79-88.	0.8	8
98	Circulating Antibodies against Epstein–Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 414-419.	1.1	8
99	Epigenetic prediction of complex traits and mortality in a cohort of individuals with oropharyngeal cancer. Clinical Epigenetics, 2020, 12, 58.	1.8	8
100	Cutaneous viral infections associated with ultraviolet radiation exposure. International Journal of Cancer, 2021, 148, 448-458.	2.3	8
101	Inequality in survival of people with head and neck cancer: Head and Neck 5000 cohort study. Head and Neck, 2021, 43, 1252-1270.	0.9	8
102	Survival advantage in patients with human papillomavirusâ€driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000. Cancer, 2021, 127, 2442-2452.	2.0	8
103	Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 39-48.	1.1	7
104	Post-treatment human papillomavirus antibody kinetics in cervical cancer patients. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180295.	1.8	6
105	Identifying epigenetic biomarkers of established prognostic factors and survival in a clinical cohort of individuals with oropharyngeal cancer. Clinical Epigenetics, 2020, 12, 95.	1.8	6
106	Seropositivity for Helicobacter pylori and hepatobiliary cancers in the PLCO study. British Journal of Cancer, 2020, 123, 909-911.	2.9	6
107	Detection of HPV16 /18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay. Laryngoscope, 2021, 131, 1042-1048.	1.1	6
108	Serological Assessment of 18 Pathogens and Risk of AIDS-Associated Non-Hodgkin Lymphoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e53-e63.	0.9	5

#	Article	IF	CITATIONS
109	Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2729-2734.	1.1	5
110	Cutaneous β HPVs, Sun Exposure, and Risk of Squamous and Basal Cell Skin Cancers in Australia. Cancer Epidemiology Biomarkers and Prevention, 2021, , .	1.1	5
111	Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into Multiplex Serology. Methods, 2019, 158, 44-53.	1.9	4
112	Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1761-1764.	1.1	4
113	Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer. Scientific Reports, 2019, 9, 10847.	1.6	3
114	Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2255-2260.	1.1	3
115	High Ambient Solar UV Correlates with Greater Beta HPV Seropositivity in New South Wales, Australia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 49-56.	1.1	3
116	Patientâ€reported swallowing function after treatment for earlyâ€stage oropharyngeal carcinoma: Populationâ€based study. Head and Neck, 2020, 42, 1981-1993.	0.9	2
117	DNA methylationâ€derived systemic inflammation indices and their association with oropharyngeal cancer risk and survival. Head and Neck, 2022, 44, 904-913.	0.9	2
118	Prevalence of Transcriptionally Active HPV Infection in Tumor-Free Oropharyngeal Tissue of OPSCC-Patients. Frontiers in Oncology, 2022, 12, 835814.	1.3	2
119	Serological and hematological characteristics of Sjogren's syndrome and dry eye syndrome patients using a novel immune serology technique. PLoS ONE, 2020, 15, e0244712.	1.1	1
120	Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany. BMC Infectious Diseases, 2022, 22, 44.	1.3	1
121	P479â€Immunoprofiling ofChlamydia trachomatiscombining whole-proteome microarrays and high-throughput multiplex serology. , 2019, , .		0
122	Human cytomegalovirus alters immune cell profile with potential implications for patient survival in head and neck cancer. Carcinogenesis, 2022, , .	1.3	0